Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

Blood

Volumn 106, Issue 8, 2005, Pages 2627-2632

  Nishimoto, Norihiro ^a   Kanakura, Yuzuru ^b   Aozasa, Katsuyuki ^b   Johkoh, Takeshi ^b   Nakamura, Minoru ^b   Nakano, Shuji ^b   Nakano, Nobuaki ^b   Ikeda, Yasuo ^b   Sasaki, Takeshi ^b   Nishioka, Kiyoshi ^b   Hara, Masamichi ^b   Taguchi, Hirokuni ^b   Kimura, Yukihiko ^b   Kato, Yoshiro ^b   Asaoku, Hideki ^b   Kumagai, Shunichi ^b   Kodama, Fumio ^b   Nakahara, Hideko ^b   Hagihara, Keisuke ^b   Yoshizaki, Kazuyuki ^b   Kishimoto, Tadamitsu ^b   more..

^a OSAKA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; CORTICOSTEROID; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; APHTHOUS STOMATITIS; ARTICLE; BODY MASS; CELLULITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FATIGUE; FEMALE; FEVER; HUMAN; INFLAMMATION; MALAISE; MALE; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RHINORRHEA; THORAX PAIN; URINARY TRACT INFECTION;

EID: 27144488346     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4602     Document Type: Article

References (21)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956;9:822-830.
2. Flendrig JA, Schillings PHM. Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl. 1969;12:119-120.
3. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670-683.
4. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3:1202-1216.
5. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol. 1993;20:636-647.
6. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86:1276-1280.
7. Dupin N, Gorin I, Deleuze J, Agut H, Huraux JM, Escande JP. Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease [letter]. N Engl J Med. 1995;333:798; discussion 798-799.
8. Gessain A, Sudaka A, Briere J, et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virusinfected patients? Blood. 1996;87:414-416.
9. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74:1360-1367.
10. Beck JT, Hsu SM, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330:602-605.
11. Simko R, Nagy K, Lombay B, et al. Multicentric Castleman disease and systemic lupus erythematosus phenotype in a boy with Klinefelter syndrome: long-term disease stabilization with interferon therapy. J Pediatr Hematol Oncol. 2000;22:180-183.
12. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi's sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98:3473-3475.
13. Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1-10.
14. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized antiinterleukin-6 receptor antibody therapy. Blood. 2000;95:56-61.
15. Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53:851-856.
16. Nishimoto N, Ito A, Ono M, et al. IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor. Int Immunol. 2000;12:187-189.
17. Yoshizaki K, Kanakura Y, Aozasa K, et al. A dose finding study of a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, MRA, in multicentric Castleman's disease [abstract]. Blood. 2002;100;363. Abstract 1404.
18. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev. 1999;20:223-248.
19. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24-29.
20. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol. 1998;9:527-534.
21. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 1996;39:1082-1091.